ACLS Stock Analysis: Axcelis Technologies | NASDAQ
Semiconductor Equipment & Materials | NASDAQ, USA | Market Cap: 2.779m USD | 12M Return: 26.5% | US0545402085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.0M
EPS Trend: -98.7%
Qual. Beats: 2
Rev. Trend: -91.6%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Axcelis Technologies (ACLS) is a U.S.-based semiconductor equipment manufacturer founded in 1978 and headquartered in Beverly, Massachusetts. The company specializes in ion implantation systems-a critical process step in semiconductor chip fabrication used to modify the electrical properties of silicon wafers through doping. Its product portfolio includes high energy, high current, and medium current implanters designed to meet varied application requirements.
In addition to new equipment sales via a direct sales force, Axcelis generates recurring revenue through an aftermarket lifecycle business that supplies used tools, spare parts, equipment upgrades, maintenance services, and customer training. The company serves chip manufacturers across the United States, Europe, and the Asia Pacific region, positioning it within the Semiconductor Materials & Equipment sub-industry of the Information Technology sector.
- SiC power device adoption accelerates ion implanter orders
- Aftermarket services revenue expands with growing installed base
- China chipmaker capex exposed to tightening export controls
| Net Income: 104.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -5.12 > 1.0 |
| NWC/Revenue: 95.65% < 20% (prev 92.02%; Δ 3.64% < -1%) |
| CFO/TA 0.05 > 3% & CFO 70.2m > Net Income 104.6m |
| Net Debt (-431.2m) to EBITDA (135.7m): -3.18 < 3 |
| Current Ratio: 4.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.1m) vs 12m ago -1.10% < -2% |
| Gross Margin: 42.81% > 18% (prev 44.68%; Δ -1.86% > 0.5%) |
| Asset Turnover: 62.93% > 50% (prev 63.10%; Δ -0.18% > 0%) |
| Interest Coverage Ratio: 20.14 > 6 (EBIT TTM 117.8m / Interest Expense TTM 5.85m) |
| A: 0.58 (Total Current Assets 1.10b - Total Current Liabilities 248.4m) / Total Assets 1.48b |
| B: 0.39 (Retained Earnings 573.8m / Total Assets 1.48b) |
| C: 0.08 (EBIT TTM 117.8m / Avg Total Assets 1.41b) |
| D: 3.06 (Book Value of Equity 1.11b / Total Liabilities 364.3m) |
| Altman-Z'' = 8.82 = AAA |
| DSRI: 1.00 (Receivables 154.7m/147.6m, Revenue 890.2m/853.1m) |
| GMI: 1.04 (GM 44.68% / 42.81%) |
| AQI: 0.95 (AQ_t 0.19 / AQ_t-1 0.20) |
| SGI: 1.04 (Revenue 890.2m / 853.1m) |
| TATA: 0.02 (NI 104.6m - CFO 70.2m) / TA 1.48b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of November 13, 2026, the stock is trading at USD 108.06 with a total of 295,732 shares traded. Over the past week, the price has changed by +20.07%, over one month by -15.33%, over three months by -23.98% and over the past year by +26.50%.
Current recommended Stop Loss: 98.10 (which is 9.2% or 1.3 ATR below the current price).
Axcelis Technologies has received a consensus analysts rating of 3.20. Therefore, it is recommended to hold ACLS.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 150 | 38.8% |
P/E Trailing = 30.2013
P/E Forward = 15.7978
P/S = 3.2091
P/B = 2.6697
P/EG = 1.4493
Revenue TTM = 890.2m USD
EBIT TTM = 117.8m USD
EBITDA TTM = 135.7m USD
Long Term Debt = 40.8m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 1.80m USD (from shortTermDebt, last quarter)
Debt = 41.2m USD (from shortLongTermDebtTotal, last quarter) (leases 41.6m already included)
Net Debt = -431.2m USD (calculated: Debt 41.2m - CCE 472.4m)
Enterprise Value = 2.35b USD (2.78b + Debt 41.2m - CCE 472.4m)
Interest Coverage Ratio = 20.14 (Ebit TTM 117.8m / Interest Expense TTM 5.85m)
EV/FCF = 39.18x (Enterprise Value 2.35b / FCF TTM 59.9m)
FCF Yield = 2.55% (FCF TTM 59.9m / Enterprise Value 2.35b)
FCF Margin = 6.73% (FCF TTM 59.9m / Revenue TTM 890.2m)
Net Margin = 11.75% (Net Income TTM 104.6m / Revenue TTM 890.2m)
Gross Margin = 42.81% ((Revenue TTM 890.2m - Cost of Revenue TTM 509.1m) / Revenue TTM)
Gross Margin QoQ = 40.97% (prev 42.38%)
Tobins Q-Ratio = 1.59 (Enterprise Value 2.35b / Total Assets 1.48b)
Interest Expense / Debt = 14.21% (Interest Expense 5.85m / Debt 41.2m)
Taxrate = 6.64% (7.44m / 112.0m)
NOPAT = 110.0m (EBIT 117.8m * (1 - 6.64%))
Current Ratio = 4.43 (Total Current Assets 1.10b / Total Current Liabilities 248.4m)
Debt / Equity = 0.04 (Debt 41.2m / totalStockholderEquity, last quarter 1.11b)
Debt / EBITDA = -3.18 (Net Debt -431.2m / EBITDA 135.7m)
Debt / FCF = -7.19 (Net Debt -431.2m / FCF TTM 59.9m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.39% (Net Income 104.6m / Total Assets 1.48b)
RoE = 9.82% (Net Income TTM 104.6m / Total Stockholder Equity 1.06b)
RoCE = 10.66% (EBIT 117.8m / Capital Employed (Equity 1.06b + L.T.Debt 40.8m))
RoIC = 9.27% (NOPAT 110.0m / Invested Capital 1.19b)
WACC = 14.39% (E(2.78b)/V(2.82b) * Re(14.41%) + D(41.2m)/V(2.82b) * Rd(14.21%) * (1-Tc(0.07)))
Discount Rate = 14.41% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: -95.10 | Cagr: -2.29%
[DCF] Terminal Value 54.09% ; FCFF base≈85.6m ; Y1≈75.0m ; Y5≈60.6m
[DCF] Fair Price = 29.93 (EV 493.2m - Net Debt -431.2m = Equity 924.4m / Shares 30.9m; r=14.39% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -98.71 | EPS CAGR: -21.14% | SUE: 0.91 | # QB: 2
Revenue Correlation: -91.63 | Revenue CAGR: -11.54% | SUE: 1.16 | # QB: 2
EPS current Quarter (2027-03-31): EPS=1.18 | Chg30d=+0.00% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=4.11 | Chg30d=+0.00% | Revisions=+57% | GrowthEPS=-15.9% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=5.27 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+28.3% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: +42% (up=7, down=2)